Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AUTL
stocks logo

AUTL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
21.13M
+72777.38%
-0.276
+206.58%
27.49M
+206.06%
-0.210
-20.33%
--
--
-0.190
+5.56%
Estimates Revision
The market is revising Upward the revenue expectations for Autolus Therapeutics plc (AUTL) for FY2025, with the revenue forecasts being adjusted by 2.98% over the past three months. During the same period, the stock price has changed by 7.53%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+21.62%
In Past 3 Month
Stock Price
Go Up
up Image
+7.53%
In Past 3 Month
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.570
sliders
Low
5.00
Averages
7.68
High
10.00
Current: 1.570
sliders
Low
5.00
Averages
7.68
High
10.00
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-04-10
Reason
Needham
Gil Blum
Price Target
$10
2025-04-10
Reiterates
Strong Buy
Reason
Truist Securities
Asthika Goonewardene
Strong Buy
Maintains
$11 → $10
2025-04-01
Reason
Truist Securities
Asthika Goonewardene
Price Target
$11 → $10
2025-04-01
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Autolus Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day.
Wells Fargo
Yanan Zhu
Buy
Maintains
$8 → $6
2025-03-21
Reason
Wells Fargo
Yanan Zhu
Price Target
$8 → $6
2025-03-21
Maintains
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-01-13
Reason
Needham
Gil Blum
Price Target
$10
2025-01-13
Reiterates
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2024-12-09
Reason
Needham
Gil Blum
Price Target
$10
2024-12-09
Reiterates
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2024-12-05
Reason
Needham
Gil Blum
Price Target
$10
2024-12-05
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Autolus Therapeutics PLC (AUTL.O) is -1.72, compared to its 5-year average forward P/E of -3.08. For a more detailed relative valuation and DCF analysis to assess Autolus Therapeutics PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.08
Current PE
-1.72
Overvalued PE
-1.38
Undervalued PE
-4.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.37
Undervalued EV/EBITDA
-3.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
134.12
Current PS
0.00
Overvalued PS
302.69
Undervalued PS
-34.45
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AUTL News & Events

Events Timeline

(ET)
2025-12-01
07:18:00
Autolus Appoints Ryan Richardson to Board of Directors
select
2025-11-25 (ET)
2025-11-25
05:08:17
Autolus Therapeutics reveals NICE draft guidance endorsing Aucatzyl
select
2025-11-12 (ET)
2025-11-12
07:03:15
Autolus Therapeutics announces Q3 earnings per share of 30 cents, surpassing consensus estimate of 23 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01Newsfilter
Autolus Appoints Ryan Richardson to Board, Aiming to Expand obe-cel's Reach
  • Strategic Leadership Enhancement: Autolus Therapeutics has appointed Ryan Richardson to its Board, bringing over 20 years of strategy and corporate development experience in healthcare and investment banking, which will significantly support the company's growth as a commercial-stage entity.
  • Market Expansion Potential: Having served as Chief Strategy Officer at BioNTech, where he was integral to the company's global expansion and IPO, Richardson's expertise is expected to help Autolus effectively expand obe-cel's market opportunities in new indications.
  • Clinical Data Support: Autolus is well-positioned with a strong foundation of clinical data supporting growth in current and future indications, combined with proven CAR T manufacturing expertise, enhancing the company's competitiveness in the biopharmaceutical market.
  • Diverse Background: Richardson holds an International MBA and a Master's from the London School of Economics, and his diverse background is anticipated to provide multifaceted perspectives on Autolus's strategic direction, aiding innovation in cancer and autoimmune disease treatments.
[object Object]
Preview
7.5
11-29Businesswire
Autel Signs Strategic MoU with UAEV to Enhance UAE EV Charging Network
  • Strategic Collaboration: Autel has signed a strategic MoU with Emarat EV Charging Stations Company to jointly develop next-generation charging and energy management technologies tailored for the UAE's climate, enhancing the reliability and performance of the EV charging infrastructure.
  • Technology Cooperation: The collaboration will focus on Vehicle-to-Grid interaction, battery energy storage systems, and intelligent charging platforms, with plans for joint research and pilot programs aimed at improving network reliability and long-term scalability.
  • Technical Strengths: Autel contributes ultra-fast DC charging systems capable of operating in temperatures exceeding 55°C, which, combined with UAEV's national strategy, supports the development of a smarter EV charging ecosystem.
  • Future Vision: UAEV plans to install over 1,000 high-speed DC chargers nationwide by 2030 to support the UAE's Net Zero 2050 Strategy, further accelerating the transition to sustainable mobility.
[object Object]
Preview
9.0
11-26Benzinga
What’s Behind the Rise in Autolus Therapeutics Stock on Tuesday?

  • NICE Draft Guidance: The U.K.’s NICE has recommended Autolus Therapeutics' Aucatzyl for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, allowing its use in the NHS.

  • Market Authorization: Aucatzyl received conditional marketing authorization from the MHRA in April 2025, based on positive results from the FELIX study.

  • Stock Performance: Autolus Therapeutics' stock (AUTL) has shown strong performance, trading at $1.38 with a notable increase of 10.48%.

  • Investment Options: Investors can buy shares of AUTL through brokerage accounts, with options for fractional shares, or engage in short selling through options trading platforms.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Autolus Therapeutics PLC (AUTL) stock price today?

The current price of AUTL is 1.57 USD — it has increased 6.08 % in the last trading day.

arrow icon

What is Autolus Therapeutics PLC (AUTL)'s business?

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

arrow icon

What is the price predicton of AUTL Stock?

Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Autolus Therapeutics PLC (AUTL)'s revenue for the last quarter?

Autolus Therapeutics PLC revenue for the last quarter amounts to 21.19M USD, decreased % YoY.

arrow icon

What is Autolus Therapeutics PLC (AUTL)'s earnings per share (EPS) for the last quarter?

Autolus Therapeutics PLC. EPS for the last quarter amounts to -0.30 USD, decreased -3.23 % YoY.

arrow icon

What changes have occurred in the market's expectations for Autolus Therapeutics PLC (AUTL)'s fundamentals?

The market is revising Upward the revenue expectations for Autolus Therapeutics plc (AUTL) for FY2025, with the revenue forecasts being adjusted by 2.98% over the past three months. During the same period, the stock price has changed by 7.53%.
arrow icon

How many employees does Autolus Therapeutics PLC (AUTL). have?

Autolus Therapeutics PLC (AUTL) has 647 emplpoyees as of December 05 2025.

arrow icon

What is Autolus Therapeutics PLC (AUTL) market cap?

Today AUTL has the market capitalization of 417.84M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free